FEATURED SEARCH TERM: prostate cancer
Joint medical societies and the FDA have weighed in publicly on the likelihood that androgen deprivation therapy for prostate cancer increases cardiovascular risk. Now a meta-analysis by authors from Harvard and MD Anderson Cancer Center holds that it does not do so. The aggregated study results do, however, confirm that it reduces the risk of dying from prostate cancer.
RESULT: Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer
JAMA | Dec 7, 2011 (Free abstract. Full text $30)
A multicenter retrospective study by different authors came to a similar conclusion a few months ago, when it was reported in a poster published alongside but not presented at the American Society for Clinical Oncology annual meeting. These researchers found an increased risk of diabetes and heart failure, but not of cardiovascular mortality, among men who had undergone androgen deprivation therapy.
RESULT: Androgen deprivation for prostate cancer and the development of cardiovascular disease, its risk factors, and all-cause mortality
ASCO Annual Meeting Abstracts | Jun 2011 (Free abstract.)
